株式会社免疫生物研究所
Immuno-Biological Laboratories Co., Ltd. is a listed company. Its directors and officers file their transactions with EDINET (Japan FSA). Between 19 October 2025 and 19 October 2026, 1 insider published 12 filings.
Not one of the filings records a straightforward purchase or sale on the market. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
No insider has bought Immuno-Biological Laboratories Co., Ltd. shares on the open market in the past twelve months.
With 12 filings in twelve months, the company is more active than the median of 3 filings across the 3,419 companies we follow on the same exchange.
These figures are compiled from regulatory filings published by EDINET (Japan FSA). They describe what insiders did and are not a recommendation.
Transparent value + quality ranking, distinct from the insider signal.
FY ended March 2026 · cache
12 of 12 declarations
Immuno-Biological Laboratory, Inc. is a Japanese company focused on the research and development of biopharmaceutical products. It specializes in immunological therapies and treatments related to autoimmune diseases.